View Item 

Show simple item record

Genetic Variants Associated With Vincristine‐Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia
dc.contributor.authorLi, Lang
dc.contributor.authorSajdyk, Tammy
dc.contributor.authorSmith, Ellen M. L.
dc.contributor.authorChang, Chien Wei
dc.contributor.authorLi, Claire
dc.contributor.authorHo, Richard H.
dc.contributor.authorHutchinson, Raymond
dc.contributor.authorWells, Elizabeth
dc.contributor.authorSkiles, Jodi L.
dc.contributor.authorWinick, Naomi
dc.contributor.authorMartin, Paul L.
dc.contributor.authorRenbarger, Jamie L.
dc.date.accessioned2019-05-31T18:25:07Z
dc.date.availableWITHHELD_14_MONTHS
dc.date.available2019-05-31T18:25:07Z
dc.date.issued2019-06
dc.identifier.citationLi, Lang; Sajdyk, Tammy; Smith, Ellen M. L.; Chang, Chien Wei; Li, Claire; Ho, Richard H.; Hutchinson, Raymond; Wells, Elizabeth; Skiles, Jodi L.; Winick, Naomi; Martin, Paul L.; Renbarger, Jamie L. (2019). "Genetic Variants Associated With Vincristine‐Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia." Clinical Pharmacology & Therapeutics 105(6): 1421-1428.
dc.identifier.issn0009-9236
dc.identifier.issn1532-6535
dc.identifier.urihttps://hdl.handle.net/2027.42/149215
dc.publisherAmerican Cancer Society
dc.publisherWiley Periodicals, Inc.
dc.titleGenetic Variants Associated With Vincristine‐Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149215/1/cpt1324_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149215/2/cpt1324.pdf
dc.identifier.doi10.1002/cpt.1324
dc.identifier.sourceClinical Pharmacology & Therapeutics
dc.identifier.citedreferenceCash, J.L. et al. Synthetic chemerin‐derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205, 767 – 775 ( 2008 ).
dc.identifier.citedreferenceUsami, S. et al. Mutations in the COCH gene are a frequent cause of autosomal dominant progressive cochleo‐vestibular dysfunction, but not of Meniere’s disease. Eur. J. Hum. Genet. 11, 744 – 748 ( 2003 ).
dc.identifier.citedreferenceOeffinger, K.C. et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572 – 1582 ( 2006 ).
dc.identifier.citedreferenceChao, C., Xu, L., Bell, E., Cooper, R. & Mueller, L. Long‐term health outcomes in survivors of childhood cancer diagnosed between 1990 and 2000 in a large US integrated health care system. J. Pediatr. Hematol. Oncol. 38, 123 – 130 ( 2016 ).
dc.identifier.citedreferenceZhang, J., Fei, T., Li, Z., Wang, L. & Chen, Y.G. BMP induces cochlin expression to facilitate self‐renewal and suppress neural differentiation of mouse embryonic stem cells. J. Biol. Chem. 288, 8053 – 8060 ( 2013 ).
dc.identifier.citedreferenceBond, A.M., Bhalala, O.G. & Kessler, J.A. The dynamic role of bone morphogenetic proteins in neural stem cell fate and maturation. Dev. Neurobiol. 72, 1068 – 1084 ( 2012 ).
dc.identifier.citedreferenceHeggeness, M.H., Strong, N., Wooley, P.H. & Yang, S.Y. Quiescent pluripotent stem cells reside within murine peripheral nerves that can be stimulated to proliferate by recombinant human bone morphogenic protein 2 or by nerve trauma. Spine J. 17, 252 – 259 ( 2017 ).
dc.identifier.citedreferenceWittamer, V. et al. Specific recruitment of antigen‐presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977 – 985 ( 2003 ).
dc.identifier.citedreferenceZabel, B.A. et al. Mast cell‐expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE‐mediated passive cutaneous anaphylaxis. J. Exp. Med. 205, 2207 – 2220 ( 2008 ).
dc.identifier.citedreferenceBozaoglu, K. et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J. Clin. Endocrinol. Metab. 95, 2476 – 2485 ( 2010 ).
dc.identifier.citedreferenceRoh, S.G. et al. Chemerin—a new adipokine that modulates adipogenesis via its own receptor. Biochem. Biophys. Res. Commun. 362, 1013 – 1018 ( 2007 ).
dc.identifier.citedreferenceMuruganandan, S., Roman, A.A. & Sinal, C.J. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J. Bone Miner. Res. 25, 222 – 234 ( 2010 ).
dc.identifier.citedreferenceSell, H. & Eckel, J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc. Nutr. Soc. 68, 378 – 384 ( 2009 ).
dc.identifier.citedreferenceEgbelakin, A. et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 56, 361 – 367 ( 2011 ).
dc.identifier.citedreferenceZabel, B.A. et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J. Biol. Chem. 280, 34661 – 34666 ( 2005 ).
dc.identifier.citedreferenceZabel, B.A. et al. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp. Hematol. 34, 1021 – 1032 ( 2006 ).
dc.identifier.citedreferenceWakao, S., Matsuse, D. & Dezawa, M. Mesenchymal stem cells as a source of Schwann cells: their anticipated use in peripheral nerve regeneration. Cells Tissues Organs 200, 31 – 41 ( 2014 ).
dc.identifier.citedreferenceZhang, J., Jin, H.C., Zhu, A.K., Ying, R.C., Wei, W. & Zhang, F.J. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides 61, 7 – 11 ( 2014 ).
dc.identifier.citedreferenceDiouf, B. et al. Association of an inherited genetic variant with vincristine‐related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313, 815 – 823 ( 2015 ).
dc.identifier.citedreferenceGutierrez‐Camino, A. et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine‐related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet. Genomics 26, 100 – 102 ( 2016 ).
dc.identifier.citedreferenceLavoie Smith, E.M. et al. Measuring vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 36, E49 – E60 ( 2013 ).
dc.identifier.citedreferenceSmith, E.M., Beck, S.L. & Cohen, J. The total neuropathy score: a tool for measuring chemotherapy‐induced peripheral neuropathy. Oncol. Nurs. Forum 35, 96 – 102 ( 2008 ).
dc.identifier.citedreferenceBosenberg, A., Thomas, J., Lopez, T., Kokinsky, E. & Larsson, L.E. Validation of a six‐graded FACES scale for evaluation of postoperative pain in children. Paediatr. Anaesth. 13, 708 – 713 ( 2003 ).
dc.identifier.citedreferenceSuha, P. Wong’s Essentials of Pediatric Nursing, 7th edn, 1307 ( Elsevier Mosby, St. Louis, MO, 2005 ).
dc.identifier.citedreferencePurcell, S. et al. PLINK: a tool set for whole‐genome association and population‐based linkage analyses. Am. J. Hum. Genet. 81, 559 – 575 ( 2007 ).
dc.identifier.citedreferencePrice, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A. & Reich, D. Principal components analysis corrects for stratification in genome‐wide association studies. Nat. Genet. 38, 904 – 909 ( 2006 ).
dc.identifier.citedreferenceTherneau, T.M. & Grambsch, P.M. Modeling Survival Data: Extending the Cox Model ( Springer, New York, 2000 ).
dc.identifier.citedreferenceAmerican Cancer Society. Cancer facts and figures. ( American Cancer Society, 2014 ). < http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-041787.pdf > (2014).
dc.identifier.citedreferenceLavoie Smith, E.M. et al. Patterns and severity of vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia. J. Peripher. Nerv. Syst. 20, 37 – 46 ( 2015 ).
dc.identifier.citedreferenceGidding, C.E., Meeuwsen‐de Boer, G.J., Koopmans, P. & de Graaf, S.S. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother. Pharmacol. 44, 203 – 209 ( 1999 ).
dc.identifier.citedreferenceToopchizadeh, V., Barzegar, M., Rezamand, A. & Feiz, A.H. Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study. J. Pediatr. Neurol. 7, 351 – 356 ( 2009 ).
dc.identifier.citedreferenceGomber, S., Dewan, P. & Chhonker, D. Vincristine induced neurotoxicity in cancer patients. Indian J. Pediatr. 77, 97 – 100 ( 2010 ).
dc.identifier.citedreferenceDennison, J.B., Jones, D.R., Renbarger, J.L. & Hall, S.D. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J. Pharmacol. Exp. Ther. 321, 553 – 563 ( 2007 ).
dc.identifier.citedreferenceDennison, J.B., Kulanthaivel, P., Barbuch, R.J., Renbarger, J.L., Ehlhardt, W.J. & Hall, S.D. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos. 34, 1317 – 1327 ( 2006 ).
dc.identifier.citedreferenceRenbarger, J.L., McCammack, K.C., Rouse, C.E. & Hall, S.D. Effect of race on vincristine‐associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr. Blood Cancer 50, 769 – 771 ( 2008 ).
dc.identifier.citedreferencePostma, T.J., Benard, B.A., Huijgens, P.C., Ossenkoppele, G.J. & Heimans, J.J. Long‐term effects of vincristine on the peripheral nervous system. J. Neurooncol. 15, 23 – 27 ( 1993 ).
dc.identifier.citedreferenceLehtinen, S.S., Huuskonen, U.E., Harila‐Saari, A.H., Tolonen, U., Vainionpää, L.K. & Lanning, B.M. Motor nervous system impairment persists in long‐term survivors of childhood acute lymphoblastic leukemia. Cancer 94, 2466 – 2473 ( 2002 ).
dc.identifier.citedreferenceWright, M.J., Halton, J.M., Martin, R.F. & Barr, R.D. Long‐term gross motor performance following treatment for acute lymphoblastic leukemia. Med. Pediatr. Oncol. 31, 86 – 90 ( 1998 ).
dc.identifier.citedreferenceNess, K.K. et al. Chemotherapy‐related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch. Phys. Med. Rehabil. 94, 1451 – 1457 ( 2013 ).
dc.identifier.citedreferenceArmstrong, G.T. et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J. Clin. Oncol. 31, 3673 – 3680 ( 2013 ).
dc.identifier.citedreferenceBarnea, D., Raghunathan, N., Friedman, D.N. & Tonorezos, E.S. Obesity and metabolic disease after childhood cancer. Oncology (Williston Park) 29, 849 – 855 ( 2015 ).
dc.identifier.citedreferenceCheung, Y.T. et al. Uric acid and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Cancer Epidemiol. Biomarkers Prev. 25, 1259 – 1267 ( 2016 ).
dc.identifier.citedreferenceChow, E.J., Pihoker, C., Hunt, K., Wilkinson, K. & Friedman, D.L. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 110, 2313 – 2320 ( 2007 ).
dc.identifier.citedreferenceOu, J.Y., Smits‐Seemann, R.R., Kaul, S., Fluchel, M.N., Sweeney, C. & Kirchhoff, A.C. Risk of hospitalization among survivors of childhood and adolescent acute lymphoblastic leukemia compared to siblings and a general population sample. Cancer Epidemiol. 49, 216 – 224 ( 2017 ).
dc.identifier.citedreferenceKhan, R.B. et al. Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross‐sectional study. J. Cancer Surviv. 8, 688 – 696 ( 2014 ).
dc.identifier.citedreferenceNess, K.K. et al. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 115, 1984 – 1994 ( 2009 ).
dc.identifier.citedreferenceMacArthur, J. et al. The new NHGRI‐EBI catalog of published genome‐wide association studies (GWAS catalog). Nucleic Acids Res 45, D896 – D901 ( 2017 ).
dc.identifier.citedreferenceMurphy, M. et al. Gene help: integrated access to genes of genomes in the reference sequence collection. < https://www.ncbi.nlm.nih.gov/books/NBK3841/ > ( 2006 ).
dc.identifier.citedreferenceRobertson, N.G. et al. Cochlin immunostaining of inner ear pathologic deposits and proteomic analysis in DFNA9 deafness and vestibular dysfunction. Hum. Mol. Genet. 15, 1071 – 1085 ( 2006 ).
dc.identifier.citedreferencePauw, R.J., Huygen, P.L., Colditz, G.M. & Cremers, C.W. Phenotype analysis of an Australian DFNA9 family with the 1109N COCH mutation. Ann. Otol. Rhinol. Laryngol. 120, 414 – 421 ( 2011 ).
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cpt1324_am.pdf
Size:
450.6KB
Format:
PDF
View/Open
Name:
cpt1324.pdf
Size:
360.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.